<DOC>
	<DOCNO>NCT02782975</DOCNO>
	<brief_summary>The primary objective study evaluate absolute bioavailability single , fix sub-cutaneous ( SC ) dose aducanumab compare single , weight-based intra-venous ( IV ) dose healthy participant characterize pharmacokinetics ( PK ) profile aducanumab . The secondary objective evaluate safety tolerability aducanumab administer via SC IV rout healthy participant characterize additional PK parameter single , fixed SC dose aducanumab weight-based IV dose healthy participant .</brief_summary>
	<brief_title>Absolute Bioavailability Single , Fixed Subcutaneous Dose Aducanumab Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Key A minimum weight 45 kg , inclusive , Day 1 . All woman childbearing potential men must practice highly effective contraception study willing able continue contraception 24 week study treatment dose ( Day 1 ) . Must good health ( determined Investigator ) base medical history screening evaluation . Key Mini mental state examination ( MMSE ) score &lt; 27 Screening . History clinically significant cardiac , endocrinologic , hematologic , hepatic , gastrointestinal , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal disease , major disease , determine Investigator . History severe allergic anaphylactic reaction opinion Investigator likely exacerbate component study treatment . History malignant disease , include solid tumor hematologic malignancy ( exception basal cell squamous cell carcinoma skin completely excise prior study entry ) . History , positive test result Screening , human immunodeficiency virus ( HIV ) . Positive test result Screening hepatitis C virus antibody ( HCVAb ) . Positive test result Screening hepatitis B virus ( defined positive , hepatitis B surface antigen [ HBsAg ] AND hepatitis B core antibody [ HBcAb ] ) . Chronic , recurrent , serious infection ( e.g. , pneumonia , septicemia ) determine Investigator , within 90 day prior Day 1 . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>